Setting up a pharmaceutical regulatory centre in India

Abstract

India’s pharmaceutical industry globally ranks among the largest, but its regulatory system struggles with issues like fragmented oversight, approval delays, and inconsistent enforcement. The COVID-19 pandemic acted as a real time demonstration of the pressing need to overhaul India's pharmaceutical regulatory system. It underscored the advantages of centralized oversight, enhanced digital infrastructure, real time monitoring, and effective communication among stakeholders. Creating a centralized regulatory body could simplify processes, improve compliance, and ensure the safety and effectiveness of medicines. This study aims the feasibility of a centralized pharmaceutical regulatory authority in India by analyzing gaps in the current system and drawing on lessons from the UK and EU frameworks to propose a practical implementation model. The research involved an analysis of regulatory frameworks, focusing on administrative structures, functions and enforcement strategies. Data were gathered from academic journals, government publications and international regulatory guidelines. Studies from India, the UK and the EU were reviewed to identify best practices and challenges. The study relied on data of global regulatory systems, with a particular focus on India’s existing regulatory framework. The analysis highlighted the fragmented nature of India’s regulatory system, with multiple agencies handling different aspects of drug regulation. In contrast, centralized systems like the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and the EU’s European Medicines Agency (EMA) showed greater efficiency and consistency. The study proposes a unified regulatory body for India, featuring clear mandates, streamlined approval processes, and strong enforcement mechanisms. The proposed National Pharmaceutical Regulatory Authority (NPRA) would function as a centralized and autonomous statutory body, integrating all pharmaceutical regulatory functions currently dispersed across Central Drugs Standard Control Organization (CDSCO) and State Drug Regulatory Authorities (SDRAs) which will operate under the Ministry of Health and Family Welfare. This advanced digital and institutional framework will help align India’s regulatory processes with those matured agencies like MHRA and EMA while addressing its unique federal structure and healthcare diversity. Establishing such a centralized pharmaceutical regulatory center in India is feasible and necessary to address current challenges. This would enhance regulatory efficiency, ensure patient safety, and align India’s pharmaceutical industry with global standards.